References
- Waits T. Introduction, Emotional Weather Report. Nighthawks at the Diner. Asylum; 1975.
- Furman RR, Grossbard ML, Johnson JL, et al. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma 2011;52:587–596.
- Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435–445.
- McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
- Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods 2005;36:3–10.
- Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low grade or transformed low grade B-cell non-Hodgkin's lymphoma. J Clin Oncol 2001;19:3918–3928.
- Kaminski MS, Tuck M, Estes J, et al. 131-I tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441–449.
- Chignola R, Pasti M, Candiandi C, et al. Escape mechanisms of humal leukemic cells to long-term immunotoxin treatment in an in vitro experimental model. Int J Cancer 1995;16:535–541.
- Brinkmann U, Brinkmann E, Pastan I, et al. Expression cloning of cDNAs that render cancer cells resistant to pseudomonas and diphtheria toxin and immunotoxins. Mol Med 1995;1:206–216.
- Kornfeld SB, Leonard JE, Mullen MD, et al. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas. Cancer Res 1991;51:1689–1693.
- Goldmaacher VS. Isolation and analysis of somatic cell mutants resistant to toxin conjugates. Cancer Treat Res 1988;37:417–430.
- Candiandi C, Franceschi A, Chignola R, et al. Blocking effect of human serum but not cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates. Cancer Res 1992;52:623–630.
- Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23:6719–6729.
- Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity on inotuzumab ozogamicin, an novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;28:2085–2093.
- Shustov AR, Advani R. Brice P, et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2010;116(Suppl. 1): Abstract 961.
- Chen R, Gopal AK, Smith SE, et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010;116(Suppl. 1): Abstract 283.
- Alduaij W, Illidge T. The future for anti-CD20 monoclonal antibodies: are we making progress? Blood 2011 Jan 5. [Epub ahead of print].